The effect of allocation to SGLT-2 inhibitors on risk of hospitalization for HF or cardiovascular death appeared similar irrespective of whether DM was present (het tests by DM status p=0.80 for the HF trials & 0.82 for the CKD trials). The gene discussed is SLC5A2; the disease is diabetes mellitus.